Psoriatic arthritis-expanding options, exciting times?

Acta Reumatologica Portuguesa

Volumn 2014, Issue 4, 2014, Pages 294-295

  McInnes, Iain B ^a   Siebert, Stefan ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHRITIS, PSORIATIC; HUMAN; TREATMENT OUTCOME;

ARTHRITIS, PSORIATIC; HUMANS; TREATMENT OUTCOME;

EID: 84930067139     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (5)

1. Tan AL, McGonagle D. Psoriatic arthritis: correlation between imaging and pathology. Joint Bone Spine 2010;77(3):206-211. doi:10.1016/j.jbspin.2009.09.011.
2. Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013;65(5):1213-1223. doi:10.1002/art.37876.
3. Frleta M, Siebert S, McInnes IB. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep 2014;16(4):414. doi:10.1007/s11926-014-0414-y
4. Sobell JM, Leonardi CL. Therapeutic development in psoriasis. Semin Cutan Med Surg. 2014;33:S69-72. doi:10.12788/j.sder.0098.
5. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-55. doi:10.1146/annurev-immunol-032713-120225